Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Carcinoma × Mitomycin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 10 Non-Muscle Invasive Bladder Neoplasms 8 Carcinoma, Transitional Cell 5 Stomach Neoplasms 4 Pancreatic Neoplasms 3 Carcinoma, Hepatocellular 3 Anus Neoplasms 3 Peritoneal Neoplasms 2 Liver Neoplasms 2 Colorectal Neoplasms 2 Appendiceal Neoplasms 2 Urethral Neoplasms 1 Ureteral Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Pseudomyxoma Peritonei 1 Neoplasm Metastasis 1 Gastrointestinal Neoplasms 1 Dermatitis 1 Carcinoma 1 Adenocarcinoma 1

Interventions

Carboplatin 21 Cisplatin 14 pembrolizumab 12 Paclitaxel 12 Gemcitabine 12 Pemetrexed 9 130-nm albumin-bound paclitaxel 9 Everolimus 8 Cetuximab 6 durvalumab 5 Fluorouracil 5 Docetaxel 5 Cyclophosphamide 5 Axitinib 5 Albumin-Bound Paclitaxel 5 osimertinib 4 Sunitinib 4 Radiotherapy 4 Nivolumab 4 Ipilimumab 4 Erlotinib Hydrochloride 4 Sorafenib 3 Radiotherapy, Intensity-Modulated 3 Radiation 3 Octreotide 3 Irinotecan 3 Bevacizumab 3 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3 vosaroxin 2 pralsetinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02793128 2020-12-22

Olympus

UroGen Pharma Ltd.

Phase 3 Completed

71 enrolled 16 charts 2 FDA

Carcinoma, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡